Virus therapy for bladder cancer.
Approximately 50,000 cases of superficial bladder cancer are diagnosed annually in the United States. Immunotherapy utilizing intravesical BCG is the most effective standard therapy for superficial transitional cell carcinoma of the bladder. Based on ease of administration, limited systemic dissemination, and the demonstrated activity of immunotherapy, superficial bladder cancer is an excellent target for virus based gene and immunotherapy. Thus far, clinical trials of virus therapy for bladder cancer have yielded mixed results. In this paper the results of several virus based clinical trials for bladder cancer are reviewed.
Burke
James
J
Billings Clinic, Department of Hematology and Oncology, United States. jburke@billingsclinic.org
D000256:Adenoviridae / Q000235:genetics / Q000502:physiology; D001500:BCG Vaccine / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D015316:Genetic Therapy; D005822:Genetic Vectors; D006801:Humans; D050130:Oncolytic Virotherapy; D001749:Urinary Bladder Neoplasms / Q000473:pathology / Q000628:therapy*; D014616:Vaccinia virus / Q000235:genetics / Q000502:physiology
D001500:BCG Vaccine